ReviewInternational journal of molecular sciences2026
Evolution of
Naoki Haratake, Shinkichi Takamori, Keisuke Shigeta, Donald Kufe
Abstract readReview
In one paragraphReview in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Naoki HaratakeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D830, Boston, MA 02215, USA.
Shinkichi TakamoriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D830, Boston, MA 02215, USA.
Keisuke ShigetaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D830, Boston, MA 02215, USA.
Donald KufeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D830, Boston, MA 02215, USA.ORCID 0000-0001-5743-8888 Funding
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast CancerR01CA097098 · NCI · DANA-FARBER CANCER INSTITUTE · PI DONALD W. KUFE · 2002 to 2026
$8.8MCombining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancerR01CA282437 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DONALD W. KUFE, Kwok Kin Wong · 2024 to 2026
$2.1MMUC1-C is a target for advancing immunotherapy of non-small cell lung cancerR21CA289134 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W. · 2024 to 2024
$450kNational Cancer Institute of the National Institutes of Health CA97098, CA282437, CA289134NCI NIH HHS R01 CA097098NCI NIH HHS R01 CA282437NCI NIH HHS R21 CA289134
6 · The paper itselfAbstract
Indexed as
Evolution, MolecularMucin-1NeoplasmsRetroelementsAnimalsEndogenous RetrovirusesHumansInterferon Type ILong Interspersed Nucleotide ElementsSignal TransductionInterferon Type IMUC1 protein, humanMucin-1RetroelementsAPOBEC3HERVIFN-ILINE-1M1CMUC1viral mimicry
Identifiers
PMID42511481
PMCPMC13410890
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390